AGEs, rather than hyperglycemia, are responsible formicrovascular complications in diabetes: A"glycoxidation-centric" point of view

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 10, 2013, Pages 913-919

  Chilelli, N C ^a   Burlina, S ^a   Lapolla, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Advanced glycation end products; Diabetes mellitus; Metabolic memory; Microvascular complications; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COLLAGEN TYPE 4; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE;

CARDIOVASCULAR DISEASE; DEMYELINATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE COURSE; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; MICROVASCULATURE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN BINDING; RESPIRATORY CHAIN; RETINOPATHY; SHORT SURVEY; TISSUE INJURY; UPREGULATION;

ADVANCED GLYCATION END PRODUCTS; DIABETES MELLITUS; METABOLIC MEMORY; MICROVASCULAR COMPLICATIONS; OXIDATIVE STRESS;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; MICROVESSELS; MODELS, BIOLOGICAL; OXIDATIVE STRESS;

EID: 84886235609     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.04.004     Document Type: Short Survey

References (49)

1. Nolan C.J., Damm P., Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011, 378:169-181.
2. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005, 54:1615-1625.
3. Piarulli F., Sartore G., Ceriello A., Ragazzi E., Reitano R., Nollino L., et al. Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia 2009, 52:1419-1425.
4. Lapolla A., Piarulli F., Sartore G., Ceriello A., Ragazzi E., Reitano R., et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007, 30:670-676.
5. Rosenson R.S., Fioretto P., Dodson P.M. Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis 2011, 218:13-18.
6. Jax T.W. Metabolic memory: a vascular perspective. Cardiovasc Diabetology 2010, 9:51.
7. Orasanu G., Plutzky J. The continuum of diabetic vascular disease: from macro- to micro- J Am Coll Cardiol 2009, 53:S35-S42.
8. Ceriello A., Inhat M.A., Thorpe J.E. The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab 2009, 94:410-415.
9. Lapolla A., Brioschi M., Banfi C., Tremoli E., Cosma C., Bonfante L., et al. Nonenzymatically glycated lipoprotein ApoA-I in plasma of diabetic and nephropathic patients. Ann N Y Acad Sci 2008, 1126:295-299.
10. Pugliese G. Do advanced glycation end products contribute to the development of long-term diabetic complications?. Nutr Metab Cardiovasc Dis 2008, 18:457-460.
11. Kalapos M.P. Where does plasma methylglyoxal originate from?. Diabetes Res Clin Pract 2012, 10.1016/j.diabres.2012.11.003.
12. Gugliucci A., Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996, 39:149-160.
13. Tessitore N., Lapolla A., Aricò N.C., Poli A., Gammaro L., Bassi A., et al. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels. J Nephrol 2004, 17(5):707-714.
14. Thomas M.C., Forbes J.M., Cooper M.E. Advanced glycation end products and diabetic nephropathy. Am J Ther 2005, 12:562-572.
15. Lapolla A., Fedele D., Seraglia R., Traldi P. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update. Mass Spectrom Rev 2006, 25:775-797.
16. Kankova K. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?. Proc Nutr Soc 2008, 67:60-74.
17. Uribarri J., Cai W., Ramdas M., Goodman S., Pyzic R., Chen X., et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes. Potential role of AGER1 and SIRT1. Diabetes Care 2011, 34:1610-1616.
18. Yamagishi S., Ueda S., Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007, 13:2832-2836.
19. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
20. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
21. Kolm-Litty V., Sauer U., Nerlich A., Lehmann R., Schleicher E.D. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 2008, 101:160-169.
22. He M., Siow R.C.M., Sugden D., Gao L., Cheng X., Mann G.E. Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes. Nutr Metab Cardiovasc Dis 2011, 21:277-285.
23. Elosta A., Ghous T., Ahmed N. Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications. Curr Diabetes Rev 2012, 8:92-108.
24. Sell D.R., Lapolla A., Odetti P., Fogarty J., Monnier V.M. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992, 41(10):1286-1292.
25. Piarulli F., Sartore G., Lapolla A. Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol 2012, 10.1007/s00592-012-0412-3.
26. Dimitriadis K., Tsioufis C., Kasiakogias A., Miliou A., Poulakis M., Kintis K., et al. Soluble receptor for advanced glycation end-products levels are related to albuminuria and arterial stiffness in essential hypertension. NMCD 2011, 10.1016/j.numecd.2011.10.003.
27. Piarulli F., Lapolla A., Ragazzi E., Susana A., Sechi A., Nollino L., et al. Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients. Atherosclerosis 2012, 736-738. pii: S0021-9150(12)00736-8.
28. Rosca M.G., Mustata T.G., Kinter M.T., Ozdemir A.M., Kern T.S., Szweda L.I., et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Ren Physiol 2005, 289:F420-F430.
29. Karachalias N., Babaei-Jadidi R., Ahmed N., Thornalley P.J. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003, 31:1423-1425.
30. Sugimoto K., Nishizawa Y., Horiuchi S., Yagihashi S. Localization in human peripheral nerve of Nε-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997, 40:1380-1387.
31. Wada R., Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 2005, 1043:598-604.
32. Duran-Jimenez B., Dobler D., Moffatt S., Rabbani N., Streuli C.H., Thornalley P.J., et al. Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 2009, 58:2893-2903.
33. Sekido H., Suzuki T., Jomori T., Takeuchi M., Yabe-Nishimura C., Yagihashi S. Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. Biochem Biophys Res Commun 2004, 320:241-248.
34. Chan L., Terashima T., Urabe H., Lin F., Kojima H. Pathogenesis of diabetic neuropathy: bad to the bone. Ann N Y Acad Sci 2011, 1240:70-76.
35. Antonietti D.A., Barber A.J., Bronson S.K., Freeman W.M., Gardner T.W., Jefferson L.S., et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006, 55:2401-2411.
36. Stitt W.A. AGEs and diabetic retinopathy. Investig Ophthalmol Vis Sci 2010, 51:4867-4874.
37. Mèndez J.D., Xie J., Aguilar-Hernàndez M., Méndez-Valenzuela V. Molecular susceptibility to glycation and its implication in diabetes mellitus and related diseases. Mol Cell Biochem 2010, 344:185-193.
38. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone J., et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111.
39. Yamagishi S., Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxidative Med Cell Longevity 2010, 3:101-108.
40. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994, 43:836-841.
41. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
42. Busch M., Franke S., Rüster C., Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010, 40:742-755.
43. Yamagishi S., Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy - friend or foe?. Pharmacol Res 2011, 64:187-194.
44. Stirban A., Tschoepe D., Stratmann B. Shifting the disease management paradigm from glucose. What are the pros?. Diabetes Care 2009, 32:S349-S352.
45. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
46. Nathan D.M., Kuenen J., Borg R., Zheng H., Schoenfeld D., Heine R.J., et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008, 31:1473-1478.
47. Lapolla A., Tubaro M., Reitano R., Aricò N.C., Ragazzi E., Seraglia R., et al. The complexity of non-enzymatic glycation product sets of human globins. Diabetologia 2004, 47:1712-1715.
48. Sartore G., Piarulli F., Ragazzi E., Burlina S., Chilelli N.C., Sarais C., et al. Subclinical diastolic dysfunction in type 2 diabetic patients with and without carotid atherosclerosis: relationship with glyco-oxidation, lipid oxidation and antioxidant status. Int J Cardiol 2011, 163(2):201-205.
49. Vlassara H., Striker G.E. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011, 24(7):526-539.